The trajectory of Sildenafil presents a nuanced case for investors in the pharmaceutical sector. While initially a tremendous success, generating vast sums, the patent lapse and the subsequent flood of off-brand https://pharma014230.actoblog.com/42710739/sildenafil-and-big-pharma-a-risky-bet